TO THE EDITOR
Adult T-cell leukemia (ATL) is a peripheral T-cell neoplasm most often composed of highly pleomorphic lymphoid cells and is caused by a human retrovirus, termed human T-cell leukemia virus type I (HTLV-I).
1,2 ATL has characteristic clinical features and the prognosis of acute and lymphoma-type patients is very poor. Recently, several studies suggested that allogeneic stem cell transplantation (allo-SCT) may improve the outcome of ATL patients, 3 probably owing to alloreactivity of donor immune cells against host ATL cells. However, further studies are needed to evaluate and improve the efficacy of all-SCT for ATL. Monitoring minimal residual disease (MRD) before and after allo-SCT has been reported to be useful for improving predictive accuracy for relapse or continuing complete remission (CR) in a variety of hematologic malignancies. In ATL patients, serum levels of soluble interleukin-2 receptor (sIL-2R) are known to correlate with tumor burden and response to therapy. 4 Recently, it was reported that HTLV-I proviral load was kept lower in two ATL patients remaining in CR after allo-SCT. 3 It would be useful to serially examine proviral load in combination with sIL-2R level during allo-SCT. In addition to these markers, HTLV-I expression level may also be a predictive marker. Tax, one of the HTLV-I viral products, is a key regulator for immortalization, transformation and oncogenesis of the HTLV-I-infected lymphocytes through its transactivation capacity of many cellular genes, 5 and also plays a role as an immunodominant target antigen for cytotoxic T lymphocytes response to HTLV-I. 6 Therefore, tax-expressing cells may easily proliferate and cause lethal disease in the immunodeficient state after allo-SCT. In the present study, we employed serial quantification of HTLV-I proviral load as MRD for patients with ATL who underwent allo-SCT, analyzed the prognostic significance of this marker and compared it with serum levels of sIL-2R. In addition, we examined the expression of HTLV-I tax mRNA in the samples during allo-SCT.
Six patients with ATL (five acute and one lymphoma type) who underwent allo-SCT between March 2000 and September 2001 at Kyoto University Hospital and Kurashiki Central Hospital (Kurashiki, Japan) were included in this study. The clinical course of these patients except patient 5 was reported elsewhere. 7 In brief, as shown in Table 1 , three patients received the myeloablative-conditioning regimen. The other three patients, who were either too old or considered unfit for the myeloablative regimen, underwent the reduced-intensity regimen. Three of the six donors were asymptomatic HTLV-I carriers (ACs).
First, we developed real-time quantitative polymerase chain reaction (RQ-PCR) using an ABI PRISM 7900HT sequence detector (Applied Biosystems, Norwalk, CT, USA) to measure HTLV-I proviral load. DNA was extracted from peripheral blood mononuclear cells (PBMCs) and 100 ng DNA was used for each PCR reaction. The sequences for primers and TaqMan probe to amplify HTLV-I pX region were as follows: forward primer 5 0 -TTTTCGGATACCCAGTCTACGTG-3 0 , reverse primer 5 0 -GAA-CATAGTCCCCCAGAGATGG-3 0 , and the probe 5 0 -TTGGA-GACTGTGTACAAGGCGACTGGTG-3 0 . As an internal control measurement to normalize for input DNA, b-actin was amplified in every sample tested. The results were corrected by defining the copy number of SYK-11L-OR cells as one per cell, because this ATL-derived cell line was shown to contain one HTLV-I provirus per cell by Southern blot analysis. SYK-11L-OR was also included in each PCR experiment. HTLV-I proviral load could be detected with a sensitivity limit as low as five copies in 10 4 PBMCs. The median numbers of HTLV-I proviral load were 8837 copies per 10 4 PBMCs (range: 1580-23 980) for 11 ATL patients (including five patients in this study) and 320 copies per 10 4 PBMCs (range: 0-3070) for 13 ACs. Then, serial quantification of HTLV-I proviral load was performed before and after allo-SCT by this RQ-PCR assay. One patient (patient 5) died of fungal infection without engraftment on day 20 after allo-SCT. Therefore, the kinetics of HTLV-I proviral load during allo-SCT was analyzed in five cases (Figure 1 ). Three patients relapsed 1, 4 and 7 months after transplantation, respectively. All three patients were in CR at the time of engraftment, and chimerism analyses using short tandem repeat markers showed complete donor type in PBMCs. An approximately 1-2-log reduction of HTLV-I proviral load was observed immediately after transplantation. However, in two of three relapsed patients (patients 1 and 6), the level of provirus increased progressively prior to the onset of hematological relapse. Patient 3 had relapse in bones and intramuscular lesions 7 months after transplantation. Surprisingly, a discontinuation of immunosuppressive agent led to almost complete regression of the tumor along with graft versus host disease (GvHD). In this case, the graft versus tumor (GVT) effect against ATL cells appeared to be evident. After achievement of CR, the level of virus load became undetectable. However, molecular remission could not be maintained and an increase in HTLV-I proviral load was observed again 1 month before the second hematological relapse. This patient died of progressive disease 20 months after allo-SCT. In two patients who achieved long-term remission after allo-SCT, HTLV-I proviral DNA was still detectable 1 month after transplantation with an approximately 2-log reduction from that at conditioning, followed by further reduction from 1 to 3 months after SCT. Finally, it became undetectable during long-term remission. Unfortunately, both patients developed severe chronic GvHD and died without relapse 10 and 16 months after transplantation. The usefulness of quantitative monitoring of HTLV-I was well illustrated in the relapse cases. The amount of provirus in these patients' PBMCs increased progressively prior to hematological relapse. In contrast, for two patients in long-term remission, a reduction of HTLV-I provirus was observed 1 month after allo-SCT, followed by a further reduction of proviral load to undetectable levels. Taken together, HTLV-I proviral load is a valuable marker for predicting the course of allo-SCT for ATL.
Serum sIL-2R levels were determined using a sandwich enzyme immunoassay and measured by SRL (Tokyo, Japan) and compared with HTLV-I proviral load. As shown in Figure 1 , there was a good correlation between all cases presented during the course of allo-SCT. In patients 1, 3 and 6, the elevation of sIL-2R level in addition to proviral load was clearly observed prior to relapse. In contrast, sIL-2R levels fluctuated up to four times the upper limit of normal, probably due to chronic GvHD in patients with long-term CR. sIL-2R was also a good marker for predicting relapse after allo-SCT. However, its levels fluctuated in patients remaining in CR, probably due to chronic GvHD, meaning that this marker may not be appropriate for predicting continuous CR. Collectively, simultaneous monitoring of proviral load and sIL-2R would be very valuable to predict the course of allo-SCT especially when fluctuations of sIL-2R levels are observed. When all the data was plotted on one graph, there was also a strong correlation between proviral load and sIL-2R level (rs ¼ 0.734, Po0.001).
Next, we quantified HTLV-I tax mRNA load at diagnosis and relapse after transplantation. Total cellular RNA was isolated by the guanidinium-phenol chloroform method. Single-strand cDNA was synthesized from 1 mg of total RNA. To quantify HTLV-I tax mRNA by RQ-PCR, the sequences of primers and TaqMan probe were designed as follows: forward primer 5 0 -CCGATCCCAAAGAAAAAGACC-3 0 , reverse primer 5 0 -GAAAA-GAAGACTCTGTCCAAACCC-3 0 , and the probe 5 0 -CCAACAC-CATGGCCCACTTCCC-3 0 . b-Actin was used as an internal control. HUT102 cells were used as a positive control. HTLV-I tax mRNA could be detected from as little as 10 7 -fold dilution of Died of fungal infection on day 20
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M, male; F, female; NR, no response; CR, complete remission; PR, partial remission; Flu, fludarabine; MEL, melphalan; CY, cyclophosphamide; TBI, total body irradiation; NE, not evaluable; PD, progressive disease; GvHD, graft versus host disease. Correspondence HUT102. By this assay, the expression of HTLV-I tax mRNA was examined in PBMC samples from five patients during the course of allo-SCT. Interestingly, HTLV-I tax expression was at a very low level in all samples (Figure 2 ). In the carrier state, HTLV-Iinfected T cells are considered to be polyclonal and to express tax gene, which is at least partially responsible for their immortalization. 5 Such immortalized T cells, derived from recipient and/or donor cells, possibly exist in ATL patients receiving allo-SCT. Tax protein is an immunodominant target antigen recognized by virus-specific T cells, and tax-expressing cells were reported to be suppressed by immune system in HTLV-I carriers. 6, 8 However, in the severe immunodeficient state such as post-SCT conditions, tax-expressing cells may expand like lymphoproliferative disorder (LPD) caused by Epstein-Barr virus (EBV). In the present study, we found that the expression of tax mRNA was scarcely detectable in all samples tested during allo-SCT. To our knowledge, polyclonal expansion of HTLV-I-infected cells has not yet been reported in patients receiving allo-SCT, including the present patients. Taken together, the expansion of such tax-expressing cells appeared to seldom occur during the course of allo-SCT.
In conclusion, both HTLV-I proviral load and sIL-2R level were able to predict relapse in patients with ATL receiving allo-SCT. Close and simultaneous monitoring of these two markers would be useful to guide the timely introduction of immunetherapeutic interventions.
Mitochondrial DNA mutations in the haematopoietic system Leukemia (2004) currently known about the role of mitochondrial DNA (mtDNA) mutations in the haematopoietic system. In addition to his previous work on myelodysplastic syndromes (MDS), 3 our recent studies 2 show that somatic mtDNA mutations are present in some patients with leukaemia. What are the wider implications of this observation?
One interpretation of our data is that clonal mtDNA mutations are present in haematopoietic stem cells. These mutations presumably accumulate with age, a phenomenon previously described in many postmitotic and dividing cells, 4 and that we have also recently observed in human colonic crypt stem cells. 5 What is still uncertain is whether the mtDNA mutations we have Figure 2 Time-point analysis for tax mRNA expression by RQ-PCR. The tax expression was serially quantified (closed circle) during the course of all-SCT. Open squares indicate hematological relapse. HUT102 cells were used as a positive control and the tax expression level in this cell line was set as 1. Dx, diagnosis.
